论文信息 - Folfoxiri plus Bevacizumab as first-line treatment of BRAF mutant metastatic colorectal cancer patients. - 字舞流文

Folfoxiri plus Bevacizumab as first-line treatment of BRAF mutant metastatic colorectal cancer patients.

G. Fontanini | C. Lupi | E. Sensi | F. Loupakis | G. Masi | A. Falcone | L. Fornaro | S. Lonardi | C. Cremolini | F. Bergamo | L. Salvatore | C. Antoniotti | M. Schirripa | Zagonel